PORT WASHINGTON, N.Y. – January 16, 2018 – Pall Corporation, a global leader in filtration, separation and purification, has been recognized as a 2017 Top 10 Innovator by The Medicine Maker Innovation Awards. The recently launched Cadence inline diafiltration (ILDF) modules were identified as one of the most exciting commercial drug development and manufacturing technologies, tools or services released onto the market in 2017. 


Launched in mid-November, the Cadence ILDF modules deliver scalable single-pass diafiltration (DF) for repeated downstream dilution and concentration cycles without a recirculation loop. In addition to enabling fully continuous DF processes in ultrafiltration and DF (UF/DF) processing steps, the modules come in a range of size formats to accommodate various processing volumes and can be used in one or more places in a continuous mAb downstream purification process. 


Held annually since 2015, The Medicine Maker Innovation Awards continue to evolve with the industry. To be eligible for the 2017 awards, entries had to be equipment, software, instruments, technology or a service relating to any area of drug development, manufacture and formulation launched between January and December 2017. 


“This award comes from our team’s dedication to innovating viable end-to-end integrated continuous bioprocessing solutions, and it is exciting to see the technology recognized,” said Mario Philips, Vice President and General Manager of Pall Life Sciences. “We are honored by the recognition and grateful to our team for their hard work and continued dedication to the effort. With this win, the Cadence portfolio has now been recognized five times by the industry over the past two years.”


To learn more about the Cadence ILDF modules, please click here. To start a conversation, please email biopharm@pall.com, or keep up with the Pall Life Sciences division on social media: LinkedInTwitterYouTube


About Pall Corporation

Pall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide.

For more information visit www.pall.com.

Or follow us on social media: Google+ - YouTube -   LinkedIn - Twitter - Facebook

Corporate Media Contact

Pall Corporation

Mariann Kourafas

Director of Communications



Media Contact

White Matter Communications

Beth Willers





More Biotech Press Releases
Read all the latest news and developments from Pall and keep in touch with industry trends and opinion.
July 2019
July 16, 2019: Servier chooses Pall as exclusive technology and services provider for planned Bio-S biomanufacturing facility in France
April 2019
April 29, 2019: Freeline's (AAV) manufacturing platform and Pall’s iCELLis bioreactor system combine to achieve commercial-scale and high quality production of AAV gene therapy vectors
March 2019
March 19, 2019: New lab will serve as a dedicated platform where the industry can access shared resources including equipment, expertise and project work to find innovative solutions to manufacturing needs for biologic medicines, such as cell-based immunotherapies
March 13, 2019: Pall Biotech to distribute ARTeSYN’s standard hardware and liner components for fluid flow control. Customers to benefit from the flexibility, agility and reliability required for their bioprocessing journey, with accelerated implementation of robust and standardized single-use fluid management and control
March 11, 2019: Pall Biotech to integrate and distribute Broadley-James’ advanced single-use probe and flow cell pH sensors; sensor will be integrated into Pall Biotech’s single-use technologies
December 2018
December 18, 2018: New centre to give Pall customers options ranging from batch to single use and continuous bioprocessing solutions, and to provide technology solutions that meet current needs, while offering some of the most progressive technological solutions for the future
November 2018
November 26, 2018: Cobra and Pall to make commercialisation of gene therapies safer, faster, and cheaper than ever before, help increase patient access to gene therapy and further establish best practices in manufacturing
October 2018
October 2, 2018: New centre will work to enhance drug production and empower the future workforce, reinforcing Pall's commitment to continuously improve bioprocesses through strategic partnerships
September 2018
September 24, 2018: New collaboration to see G-CON PODs customized with Pall technologies, addressing customer demand for higher efficiencies, while enjoying more flexibility through scale-out and localization of manufacturing
September 11, 2018: Pall and Aetos partner to combine bioreactors, mixing and storage, and downstream technologies with cell lines and manufacturing processes for expedited biosimilars development